Seroatlas · Human Serome Atlas

PRAMEF10

PRAME family member 10

Also known as: PRA10_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: O60809
Gene: PRAMEF10
Ensembl: ENSG00000187545
Chromosome: 1
Canonical length: 474 aa
Protein class: Predicted intracellular proteins

OverviewNCBI Gene

Predicted to enable ubiquitin-like ligase-substrate adaptor activity. Predicted to be involved in proteasome-mediated ubiquitin-dependent protein catabolic process. Predicted to be part of Cul2-RING ubiquitin ligase complex. Predicted to be active in cytoplasm. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

474 residues, UniProt reviewed canonical sequence.

>O60809|PRAMEF10
     1  MSLQAPSRLL ELAGQSLLRN QFLTIFTLDE LPREVFPLMF MEAFSMRRFE ALKLMVQAWP
    61  FLRLPLGSLM KTPHLETLQA VLRGLDTLVA QKVRPRRWKL QVLDLRDVDE NFWTIWSGAR
   121  VLSCSPEAMS KRQTVEDCPR MGERQPLKVF IDLCLKESTL DECLSYLFGW IHYRRGLVHL
   181  CCSKVQNYSM PTSSFRNLLE RIYPDSIQEL EVWKKCSLNK TGKFAPYLSQ MSNLRELFLA
   241  FGYERELYVS VQWPCIPDLD SPFLCLYYPQ MLYIKKISNI KEHLEHLLRY LKNPLGAFIF
   301  SDAYLTDRDM ECLSQYPSLS QLKELRLIHI LMWTTNLEPL GVLLEKVAAT LKTLVLKDCR
   361  IQDPQLRVLL PALSHCSQLT TFNFHGNETS MNALKDLLRH TRGLSKLGLE LYPAPLESLD
   421  YKGHVNWEIL TPIRAELMRT LREVRQPKRI FFGPVPCPNC GSWPSEKVDF HLCS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PRAMEF10 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.29
Highest tissue expression: 2.1 nTPM

Expression across tissuesHPA

Tissue

liver: 2.1 nTPM
adipose tissue: 0 nTPM
adrenal gland: 0 nTPM
amygdala: 0 nTPM
appendix: 0 nTPM
basal ganglia: 0 nTPM

Single-cell type

adipocytes: 0 nCPM
adrenal cortex cells: 0 nCPM
adrenal medulla cells: 0 nCPM
alveolar cells type 1: 0 nCPM
alveolar cells type 2: 0 nCPM
astrocytes: 0 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

amygdala: 0 nTPM
basal ganglia: 0 nTPM
cerebellum: 0 nTPM
cerebral cortex: 0 nTPM
choroid plexus: 0 nTPM
hippocampal formation: 0 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.54
gnomAD pLI: 0
gnomAD missense Z: -1.57

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

ubiquitin-like ligase-substrate adaptor activity

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PRAMEF10 as an antibody target. Whether an autoantibody or antibody against PRAMEF10 could matter depends on whether native PRAMEF10 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PRAMEF10 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label PRAMEF10 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...